Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $91.20 Consensus Price Target from Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given an average recommendation of “Moderate Buy” by the thirteen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $91.20.

HALO has been the subject of several recent analyst reports. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. UBS Group reissued a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $115.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $107.39 on Friday. The business’s 50-day simple moving average is $92.62 and its two-hundred day simple moving average is $76.50. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $111.15. The stock has a market cap of $12.19 billion, a PE ratio of 32.06, a P/E/G ratio of 0.42 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter in the prior year, the company posted $1.54 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts forecast that Halozyme Therapeutics will post 7.98 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 32,478 shares of company stock worth $3,076,604. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of HALO. MidFirst Bank bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $27,000. Larson Financial Group LLC grew its position in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics in the second quarter worth about $28,000. Measured Wealth Private Client Group LLC increased its stake in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Halozyme Therapeutics during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.